Maggie L. Shaw

Many people believe health equity is such a big issue that there is not much an individual practice can do to address it, explained Susan Sabo-Wagner, MSN, RN, OCN, executive director of clinical strategy, Oncology Consultants of Houston.

Data from the LIBERTY AD PRESCHOOL trial, and its ongoing open-label extension analysis show that dupilumab is safe and clinically effective, and can lead to statistically significant symptom improvement among patients aged 6 months to 17 years who have moderate to severe atopic dermatitis (AD).

Baseline risk assessment that includes prior treatment history for cancer, prior cardiovascular events, and markers for potential heart damage are all important, emphasizes Tochi M. Okwuosa, DO, cardiologist and director of cardio-oncology at Rush University Medical Center in Chicago.

Subanalyses of data from the LIBERTY PN-PRIME and LIBERTY PN-PRIME2 studies illustrate how dupilumab for prurigo nodularis can better patient outcomes, including quality of life and symptom burden.

Investigators of this study noted the need for more data on risks of malignancies among patients who have atopic dermatitis (AD), with the chronic skin condition already having significant associations with nonmelanoma skin cancer, lymphoma, keratinocyte carcinoma, and pancreatic and kidney cancers.

Stephen M. Schleicher, MD, MBA, Tennessee Oncology and Community Oncology Alliance (COA) Board of Directors member, discusses what brings him back to the Community Oncology Conference year after year.

AMCP 2023, taking place March 21-24 in San Antonio, Texas, will feature 6 educational tracks, 3 keynote addresses, and an estimated 4000 managed care professionals in attendance.

The Skin Pain Numeric Rating Scale, Worst-Itch Numeric Rating Scale, and Dermatology Life Quality Index were evaluated for their content validity, fit-for-purpose, and psychometric and measurement properties among patients with the chronic skin disease being treated with dupilumab.

In this preview of the 2023 Community Oncology Conference, past president of the Community Oncology Alliance, David Eagle, MD, of New York Cancer & Blood Specialists, discusses what has him excited for this year's meeting, both sessions and speakers.

Jeff Hunnicutt, CEO of Highlands Oncology Group, explains the 2 risk options provided under the Enhancing Oncology Model (EOM) and why the mandatory downside risk might give pause to practices that saw some success in the Oncology Care Model.

As scientists are identifying molecular alterations in patients with later-stage cancers that may be targets in earlier-stage disease, next-generation sequencing is being utilized more in the first-line setting, noted Sigrun Hallmeyer, MD, medical oncologist with Advocate Health.

Kevin Davies, PhD, executive editor, The CRISPR Journal and GEN Biotechnology, discusses how CRISPR has evolved from the initial discovery of the double helix to now, with the technology holding great promise for both genetic diseases and cancers.

Andre Harvin, PharmD, MS, MBA, Cone Health Cancer Center, discusses the vital role of pharmacists in oncology: how they use data to streamline patient visits, work to facilitate patient access to biosimilars, and advocate for their patients.

The supplemental Biologics License Application was filed for the new indication for dupilumab, which is already approved to treat atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.

Olalekan Ajayi, PharmD, MBA, chief operating officer of Highlands Oncology Group, PA, and 2023-2024 president-elect of the Association of Community Cancer Centers (ACCC), discusses why he is excited for this year’s meeting, including its many workshops and day 1 keynote on CRISPR.

Carolina Blood and Cancer Care Associates’ No One Left Alone initiative works to dismantle cancer health disparities and increase health care equity among its rural patient population. Sashi Naidu, MD, director of research, discusses delivering next-generation sequencing testing to patients.

Potential disparities in care highlight the great need for tailored cardiovascular health (CVH) interventions among bisexual female individuals, according to a recent study.

The 2 therapies, a 1-food and a 6-food elimination diet both used for eosinophilic esophagitis (EoE), were compared for outcomes after 6 weeks.

Deepak L. Bhatt, MD, MPH, Icahn School of Medicine at Mount Sinai, has multiple presentations during the upcoming American College of Cardiology Scientific Sessions, including additional phase 2 results from the ENTRIGUE trial for pegozafermin in severe hypertriglyceridemia. 

Stephen M. Schleicher, MD, MBA, chief medical officer at Tennessee Oncology, discusses the present state of value-based oncology care and what the future may bring when the Enhancing Oncology Model kicks off on July 1.

Study results presented at this year’s American Academy of Allergy Asthma & Immunology annual meeting displayed dupilumab efficacy in children aged 6 months to 5 years who had atopic dermatitis (AD).

Outcomes from the loop diuretics were compared in this analysis, with study participants from the TRANSFORM-HF trial matched 1:1, all having been hospitalized for either do novo disease or worsening chronic disease.

David A. Eagle, MD, New York Cancer & Blood Specialists, discusses the present state of treatment for cancer, which often sees patient financial concerns outweighed by the cost of treatment.

In this analysis, evidence was reviewed for the effectiveness of intranasal corticosteroids, biologics, and aspirin therapy after desensitization use among patients who have chronic rhinosinusitis with nasal polyposis (CRSwNP).

Tochi M. Okwuosa, DO, Rush University Medical Center, discusses ways in which cancer treatments can adversely affect heart health outcomes for patients under the care of oncologists.

Investigators compared these outcomes due to limited research in the space, with previous surveys suggesting care disparities.

We’ve found through health equity initiatives that the search for the right telehealth modality is never ending, explained Oncology Consultants of Houston’s Susan Sabo-Wagner, MSN, RN, OCN, executive director of clinical strategy.

This review and meta-analysis included 34 studies covering 1762 patients, and investigated the efficacy of 4 varieties of dietary treatment for eosinophilic esophagitis (EoE).

At Carolina Blood and Cancer Care Associates, the No One Left Alone (NOLA) initiative is working to break down cancer health disparities among its patients by addressing the social determinants of health that may be preventing equitable access to care.